Moleculin Biotech Financials - Benzinga

Moleculin Biotech Inc

MBRXNASDAQ

Trade with Public

Trade with Public

$0.5906

0.01863.25%

At close: Aug 20, 5:00 PM EST

$0.6000

0.00941.59%

After Hours: 5:20 PM EST

Earnings: Q2 2026 Earnings were released on Fri Aug 14th, before the market open

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Moleculin Biotech Financials

Moleculin Biotech (MBRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share

Benzinga Newsdesk

PRO
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share

Benzinga Newsdesk

PRO
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per

Benzinga Newsdesk

Nasdaq Surges 100 Points; Dollar General Earnings Beat Views

Avi Kapoor

US Stocks Mixed; Nvidia Posts Upbeat Earnings

Avi Kapoor

PRO
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share

Benzinga Newsdesk